At the traditional BioM end-of-year dinner, this time host Prof. Horst Domdey looked back not only on an eventful year for the biotechnology and pharmaceutical industry, but also on a quarter of a century as managing director of BioM. After 25 years, he will hand over the management to his successor, Prof. Ralf Huss, on […]
continue reading
At BioM’s 12th BioAngels Pitch Day on December 6, promising start-ups again met potential investors. Eight selected start-up teams had the opportunity to present their business idea in front of venture capital investors and business angels from the Life Science sector. Once again, the great potential of the Bavarian start-up scene with innovative ideas in […]
continue reading
Beim 12. BioAngels Pitch Day von BioM trafen am 6. Dezember wieder vielversprechende Start-ups auf potenzielle Kapitalgeber. Acht ausgewählte Gründerteams hatten die Möglichkeit, ihre Geschäftsidee vor Venture Capital Investoren und Business Angels aus dem Life Science Bereich zu präsentieren. Erneut zeigte sich das große Potential der bayerischen Start-up-Szene mit innovativen Ideen in den Bereichen Medikamentenentwicklung, […]
continue reading
As part of this year’s BioTech Bootcamp of BioM Biotech Cluster GmbH and the life science business incubator "SmiLe Incubator" from Lund, Sweden, the international, eight-week training program for prospective founders and young companies climaxed in the Munich “Demo Week”. Ten teams, aiming to develop and commercialize their biotech business idea, showed on the Martinsried […]
continue reading
Im Rahmen des diesjährigen BioTech Bootcamps der BioM Biotech Cluster GmbH und des Life Science Business – Inkubators „SmiLe Incubator“ aus Lund, Schweden, fand das internationale, achtwöchige Trainingsprogramm für angehende Gründer und junge Unternehmen in der Munich Demo Week seinen Höhepunkt. Zehn Teams, die ihre Biotech-Geschäftsidee entwickeln und kommerzialisieren wollen, zeigten auf dem Campus Martinsried […]
continue reading
The cluster management organizations BioM, Munich, Germany, and Osaka Bio Headquarters, Osaka, Japan, officially announced the renewal of their long-standing Transnational Biotech & Life Sciences Cooperation Partnership Agreement at the EU-Japan Biotech & Pharma Partnering Conference 2022 in Osaka. Considering the numerous deals and long-term partnerships between Bavarian biotech companies and Japanese pharmaceutical companies, it […]
continue reading
Die Clustermanagement-Organisationen BioM, München, und Osaka Bio Headquarters, Osaka, Japan, haben auf der EU-Japan Biotech & Pharma Partnering Conference 2022 in Osaka offiziell die Erneuerung ihrer langjährigen transnationalen Biotech & Life Sciences Kooperationsvereinbarung bekannt gegeben. Betrachtet man die zahlreichen Geschäftsabschlüsse und langfristigen Partnerschaften zwischen bayerischen Biotech-Unternehmen und japanischen Pharmaunternehmen, so zeigt sich, dass Japan für […]
continue reading
Munich-based BioM Biotech Cluster Development GmbH and the Deutsches Herzzentrum München hosted the annual DigiMed Bayern Symposium 2022: Big Data and AI: Can Medicine Do the Doable? on October 6 at the Gene Center Munich. This year, the DigiMed Bayern partners discussed together with top-class speakers from international politics, medical research, and industry: about successful […]
continue reading
Die Münchner BioM Biotech Cluster Development GmbH und das Deutsche Herzzentrum München veranstalteten am 6. Oktober im Genzentrum München das jährliche DigiMed Bayern Symposium 2022: Big Data and AI: Can Medicine Do the Doable?. In diesem Jahr diskutierten die DigiMed Bayern-Partner gemeinsam mit hochkarätigen Referenten aus internationaler Politik, medizinischer Forschung und Industrie: Über erfolgreiche Projektbeispiele […]
continue reading
Prof. Dr. Ralf Huss will become the new managing director of BioM Biotech Cluster Development GmbH, effective of January 1st, 2023, succeeding Prof. Dr. Horst Domdey, who will be retiring. Prof. Huss has many years of experience in academic research and international pharmaceutical companies. After his studies in medicine and research stays in Switzerland and […]
continue reading